News

Innovative therapies in cardiometabolic and nutrition-related disorders

ICAN’s mission is to accelerate the development of specific therapies by leveraging the scientific excellence of its heart and metabolism community with cutting-edge translational research, improved care, training, and effective communication. Following are several recent therapeutic highlights from each of our...
Read more

partager sur facebook

New treatment for rare genetic obesity

A new drug trial results in significant weight loss for patients with a rare genetic obesity     ICAN investigators along with German colleagues and Rhythm Pharmaceuticals have recently published Phase 2 clinical data in the New England Journal of Medicine...
Read more

partager sur facebook